Israel Based Study Shows Omicron Adapted Vaccine Shots Cut Hospitalization Rates In Elderly

  • Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer Inc PFE and BioNTech SE BNTX reduced hospitalizations among older patients.
  • The study has not yet been peer-reviewed.
  • Data exhibited an 81% reduction in hospitalizations among people aged 65 and older who had received the booster against those who had previously received at least two COVID vaccinations but not the omicron-adapted shot.
  • Related: FDA Authorizes Pfizer/BioNTech And Moderna's Bivalent COVID Shots For 6 Months Old.
  • The study was conducted among around 622,700 people who were eligible for the bivalent booster between September to mid-December. Reuters reported that 85,314, or 14%, had received it.
  • The study said that hospitalization due to Covid-19 occurred in 6 bivalent recipients and 297 participants who did not" receive it. "Death due to Covid-19 occurred in 1 bivalent recipient and 73 participants who did not."
  • Though the 86% drop in mortality was statistically borderline because of the relatively low death rates in the country, it was nonetheless significant, the researchers said.
  • Price Action: PFE shares are down 2.77% at $49.51, and BNTX shares are up 0.67% at $151.09 on the last check Monday.
  • Photo via Wikimedia Commons
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!